Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions
The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Biotech company Regeneron (NASDAQREGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share was 7.8% above analysts’ consensus estimates.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
TARRYTOWN, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQREGN) today announced financial results for the fourth quarter and full year 2024 and provided a business update.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQREGN) on behalf of long-term stockholders following a class action complaint that was filed against Regeneron on January 7, 2025 with a Class Period from November 2, 2023 to October 30, 2024. Our investigation concerns whether the board of directors of Regeneron have breached their fiduciary duties to the company.
The Regeneron Science Talent Search Celebrates and Rewards Today’s Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQREGN) and certain of its officers.
PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQREGN). The lawsuit has been filed on behalf of purchasers of Regeneron securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).
SAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQREGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
PHILADELPHIA, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) on behalf of purchasers of Regeneron securities between November 2, 2023 through October 30, 2024, inclusive (the “Class Period”).
